News

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

Biogen Reports First Quarter 2024 Results

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application

Biogen to Participate in the Stifel 2024 Virtual CNS Days

Eisai to Host Annual Information Meeting with Update on LEQEMBI® (lecanemab-irmb)

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Biogen to Participate in the TD Cowen 44th Annual Health Care Conference